ANALYSIS: Four deaths in ten years: What Health Canada Was Hiding About Plasma Donation in Canada

From Volunteering to Compensation: A National Divide

Canada is one of the few countries in the world where a provincial divide persists regarding compensation for plasma donors. In Quebec, the law prohibits payment for blood and plasma donations—a stance fiercely defended by Héma-Québec and supported by a large portion of the medical community, which believes that compensation compromises the system’s safety by attracting donors who might conceal medical information in order to be accepted. In the rest of Canada, several private centers—notably the Canadian Plasma Resources clinics—offer financial compensation of up to $50 to $80 per visit.

This divergence creates deep tensions. On one side are provinces that argue that compensation is necessary to meet required collection volumes and reduce Canada’s dependence on U.S. plasma imports. On the other, Quebec and part of the medical community maintain that donor safety and plasma quality are better guaranteed in a volunteer system, where donors have no financial incentive to conceal their health issues. In this debate, the four deaths revealed by Health Canada do not fall on deaf ears: they land right in the middle of an ideological and regulatory minefield.

Global Demand Shows No Signs of Slowing

Behind the Canadian debate lies a global economic reality. Demand for intravenous immunoglobulins (IVIG), derived from plasma, has grown at an average annual rate of 8 to 10% over the past decade. These medications have become indispensable for treating a growing range of autoimmune diseases, primary and secondary immunodeficiencies, and certain forms of polyneuropathies. The global market for plasma-derived medications is valued at over 40 billion U.S. dollars annually, and projections for 2030 exceed 70 billion.

Canada, which imports a significant portion of its plasma from the United States—a country where donor compensation has been the norm for decades—is seeking to increase its domestic production. The expansion of private collection centers in Manitoba, Ontario, and Alberta should be viewed in this context. But this expansion has taken place within a regulatory framework that, according to several experts, has not kept pace with the growth. Oversight standards, emergency protocols, and staff training at certain private centers had been called into question long before these deaths became public.

When the global pharmaceutical industry pressures a national healthcare system to produce more, faster, someone must ensure that donors do not pay the price for this acceleration.

Federal Regulations Under the Microscope

In Canada, plasma collection is governed by the Blood Regulations administered by Health Canada, which came into effect in 2014. These regulations impose strict standards on collection facilities regarding donor selection, screening tests, plasma processing, and record-keeping. They also require that any serious incident—including deaths—be reported to Health Canada within specific timeframes.

On paper, the system appears robust. In practice, however, on-the-ground oversight raises questions. How many unannounced inspections does Health Canada conduct each year at private collection centers? What criteria trigger a thorough investigation following an incident? What is the agency’s actual capacity to analyze the vigilance data submitted to it and to draw systemic lessons from it? These questions are not rhetorical. They lie at the heart of what the revelation of the four deaths compels us to examine. For if the regulatory framework were adequate, how can we explain that information about these deaths was not proactively shared with the public?

The Gray Areas Between Health Canada and the Operators

One of the structural problems with Canada’s plasma collection system is the dilution of responsibilities among the various stakeholders. Health Canada sets the standards. The provinces may add additional requirements. Center operators—whether public, like Héma-Québec, or private, like Canadian Plasma Resources—are responsible for the day-to-day implementation of protocols. And the licensed physicians who oversee the procedures have their own professional obligations.

When a donor dies, who is responsible? The answer is not always clear, and this ambiguity can slow down investigations, diffuse accountability, and—in the worst-case scenario—prevent crucial lessons from ever being learned. Do the four deaths that occurred in Manitoba and Quebec involve the same types of centers? The same flawed protocols? The same ignored risk factors? Without full transparency, it is impossible to answer these questions. And without answers, it is impossible to guarantee that a fifth death will not occur.

A regulatory framework that is not accountable to the public it is supposed to protect is not a shield—it is a facade.

A Revealing Demographic Profile

To understand the human issues behind these deaths, we must understand who donates plasma in Canada. Volunteer donors—as in Quebec—generally fit a broad profile: healthy adults motivated by altruism, often regulars in the blood donation system who wish to go a step further. But at centers that offer financial compensation, the profile changes. Studies in the U.S. and Canada show that compensation more often attracts people with modest incomes, students, part-time workers, and individuals who need the money and may be tempted to downplay certain symptoms or medical history to avoid being disqualified.

This is not a moral judgment on these donors—it is an economic reality that creates a structural medical risk. If a donor conceals that they have taken medications incompatible with the procedure, that they are dehydrated, that they have an undiagnosed heart condition, or that they have not slept for 24 hours, the chain of medical screening measures intended to protect them may be compromised. Health questionnaires, no matter how rigorous, rely on the donor’s honesty. And that honesty can be undermined by a financial incentive.

The Real Risks of Plasmapheresis

Plasmapheresis is a medical procedure—not a routine blood draw. It takes longer, places greater strain on the cardiovascular system, and involves the reinfusion of fluids and anticoagulants into the donor’s body. The most common risks are minor: dizziness, nausea, bruising at the puncture site, and mild reactions to the sodium citrate used as an anticoagulant. But in rare cases, serious complications can occur: severe vagal reaction, gas embolism, systemic allergic reaction, and cardiovascular failure.

For donors who are in perfect health, properly screened, and properly monitored, these serious risks are extremely low. But “extremely low” is not “zero.” And when tens of thousands of plasma donations are made each year at centers across the country, even a minuscule risk statistically translates into incidents. The question, therefore, is not whether complications can occur—they can. The question is whether the systems for early detection, emergency response, and post-procedure care are sufficient to minimize deaths when something goes wrong.

We’re not asking for the impossible—we’re asking that every donor who enters a center leave it alive. That’s the bare minimum. And that minimum hasn’t always been guaranteed.

A Province at the Center of the Controversy Over Compensation

Manitoba is one of the provinces that has resisted the opening of paid plasma collection centers the longest. For years, Winnipeg was the scene of intense debates between supporters of expanding private collection and advocates of an entirely volunteer-based system. When the first Canadian Plasma Resources centers finally opened in the province, the controversy did not die down—it took on a new form, one that was more concrete, more medical, and more urgent.

The deaths that have occurred in Manitoba—the exact number in this province is not specified in the available information—are part of this context of ongoing tension. Patient advocacy groups and healthcare workers’ unions had already alerted authorities to potential gaps in monitoring protocols at private centers. Were these warnings heeded? Were inspections stepped up accordingly? Were incident reports effectively shared between operators and Health Canada? These questions remain unanswered publicly—which is, in itself, an answer.

Héma-Québec and the Volunteer Defense Line

In Quebec, the situation is different but just as troubling. Héma-Québec, which operates entirely on a volunteer basis and is subject to rigorous oversight, has nonetheless experienced at least one death linked to plasma donation within its jurisdiction. This does not fundamentally call into question the volunteer model—the risks inherent in the medical procedure exist regardless of the method of compensation—but it serves as a reminder that no system is immune.

What sets the Quebec model apart is the institutional response expected following such an event. Héma-Québec is subject to transparency obligations toward the Ministry of Health and Social Services and, by extension, toward the public. In an integrated system, the death of a donor should trigger a systemic review of protocols, public communication, and documented changes. The question is whether this has happened—and if the answer is no, why not.

Whether a death occurs at a for-profit private center or a volunteer-run public center, the follow-up question must always be the same: What changes do we need to make to ensure this doesn’t happen again?

The Scientific Debate on the Quality of Paid Plasma

One of the most heated controversies in the field of plasma donation concerns the quality of plasma collected from paid donors compared to that from volunteer donors. Proponents of compensation—particularly patient advocacy groups that rely on plasma-derived medications—argue that studies show no significant difference in quality, and that compensation is the only way to achieve the volumes needed to prevent potentially life-threatening shortages for patients with rare diseases.

Opponents of compensation—including the National Advisory Committee on Blood and Blood Products and several experts from the World Health Organization—maintain that voluntary donation is inherently safer because it does not create economic pressure on the donor to conceal medical information. They also cite data on the overexploitation of paid donors—some of whom are tempted to donate more frequently than the recommended medical limits to maximize their income—which can lead to immunoglobulin deficiencies and weaken their immune systems in the long term.

Financial Incentives vs. Donor Safety

Beyond the quality of the plasma, it is the safety of the donor themselves that is at stake in this debate. A paid donor who knows they will be excluded if they disclose certain health issues is in a structurally different position from a volunteer donor. Economic pressure—even if slight or unconscious—can compromise the reliability of self-reported medical information. And during a plasmapheresis procedure, a donor with an undiagnosed heart condition, undetected mild anemia, or incompatible medication may be exposed to life-threatening risks.

The four deaths that occurred in Canada inevitably raise this question: among these donors, were there any who had risk factors that should have been detected during the screening process? Were there any who had downplayed medical information? Were there any whose deaths could have been prevented with a more rigorous monitoring protocol during the procedure? Without access to the full investigation reports, it is impossible to answer these questions. But the lack of a clear official response creates a dangerous void in public trust.

Putting a price on self-sacrifice is not a neutral act. It changes the nature of the relationship between the donor and the system—and sometimes, it also changes the nature of the risk.

Victims Without a Public Face

Behind every number is a human being. Behind the four deaths recorded by Health Canada are four people who left their homes one morning, drove to a testing site, filled out a form, rolled up their sleeves—and never returned. There are families who have received terrible news, who have had to cope with grief under particularly difficult circumstances: their loved one did not die from an expected illness or a traffic accident. They died while trying to help others. The harshness of this paradox is immense.

To date, none of these families has been publicly identified—which is appropriate to protect their privacy. But this also means that their experiences, their questions, their pain, and the answers they have or have not received from the authorities remain invisible. Has there been any compensation? Any independent investigations? Have changes to protocols been formally communicated to these families? Canadian law provides support mechanisms for victims of medical incidents, but are these mechanisms systematically activated in the context of plasma donation? These questions deserve public answers.

Donors’ Right to Information

In Canada, there is an implicit right to information for anyone undergoing a medical procedure. This right is enshrined in the principles of informed consent: a patient—or a donor—must receive all relevant information about the risks of a procedure before deciding to participate. However, if Health Canada and blood collection center operators knew that four donors had died over the past ten years, was this information systematically included in the pre-donation information sessions?

This is not about scaring donors. Such a low risk of death—out of hundreds of thousands of donations made each year—does not warrant alarmism. But the right to transparency is fundamental to the relationship between a healthcare system and the people who entrust their bodies to it. Knowing that a procedure is not entirely risk-free is not a reason not to donate—it is a prerequisite for respecting the donor’s human dignity.

An informed donor is a respected donor. A donor who is kept in the dark to prevent them from refusing to donate—that is an exploited donor.

Patients Waiting, a Chain Under Pressure

It would be incomplete to discuss the risks of plasma donation without addressing the other side of the equation: the thousands of Canadian patients whose lives depend on plasma-derived medications. People with primary immunodeficiencies, chronic inflammatory neuropathies, and certain forms of hemophilia regularly receive infusions of immunoglobulins or other plasma proteins that keep their immune systems functioning and allow them to live normal lives.

For these patients, a plasma shortage is not an economic abstraction. It is a direct threat to their health and survival. Canada currently imports a significant proportion of the plasma-derived products it consumes, primarily from the United States. This dependence is both costly and risky: a disruption in the U.S. supply chain, a regulatory change, or a public health crisis could create shortages in Canada with immediate consequences for patients who are already vulnerable. The pressure to increase domestic collection is therefore real, legitimate, and urgent.

When the needs of some create risks for others

It is within this context that we must understand the central ethical dilemma of this issue. On one side are donors who take a medical risk to sustain a system. On the other side are patients who are suffering and who need this system to survive. In between are regulatory authorities who must balance the safety of some with access to treatment for others, against a backdrop of growing demand and limited budgetary resources.

But this very real tension cannot serve as justification for downplaying the risks to donors. Medical ethics are clear on this point: it is unacceptable for people to be exposed to increased risks in the name of collective needs without their informed consent, without maximum oversight, and without full and complete accountability when accidents occur. The four deaths are not an “acceptable cost” of the system. They are failures that call for a systemic response.

The medical necessity of a product never justifies compromising the safety of those who produce it. This principle is non-negotiable.

European Models for Plasma Donation Monitoring

France, Germany, and the United Kingdom have developed approaches to plasma donation oversight that are worth examining in the Canadian context. In France, plasma collection is managed entirely by the Établissement français du sang (EFS), a public agency that operates on a strictly unpaid basis and publishes detailed annual reports on donor safety incidents, including deaths and serious complications. This systemic transparency does not prevent accidents—they occur everywhere—but it fosters a culture of continuous improvement based on publicly accessible data.

In Germany, paid plasma collection coexists with voluntary donation, but under very close oversight by the Paul Ehrlich Institute. Data on serious incidents are collected nationally, analyzed annually, and the results are published along with concrete recommendations. The German model is often cited as an example of how paid collection and rigorous transparency can coexist—a combination that Canada is still struggling to achieve.

Lessons from the United States

The United States presents a particularly instructive case study. As the world’s leading country in paid plasma collection, it supplies approximately 70% of the global market for plasma-derived products. The Food and Drug Administration (FDA) exercises strict federal oversight of collection centers, but the U.S. model is also one in which scandals have regularly erupted over collection conditions, pressure exerted on vulnerable donors, and deaths that have occurred at less scrupulous centers.

What the U.S. experience teaches us is that a rapidly expanding plasma collection sector, dominated by private operators focused on profitability, requires extremely robust regulatory oversight to prevent abuses. The FDA has significant inspection and enforcement powers. Does Health Canada have comparable powers—and, more importantly, the human resources to exercise them? The answer to this question directly determines the safety of future Canadian donors.

Canada isn’t reinventing the wheel. Similar countries have developed systems to ensure transparency regarding plasma donation incidents. All it takes is a decision to follow their example.

Calls from the Medical Community

Since these deaths came to light, several experts have spoken out to call for concrete changes. Their demands center on three main areas. First, the full publication of the investigation reports on the four deaths, with appropriate anonymization of personal data but complete transparency regarding the circumstances, the protocols in effect, and the recommendations resulting from the investigations. Second, the creation of a public national registry of serious incidents related to plasma donation, accessible to all citizens, updated in near real time, and capable of detecting risk patterns before they lead to further tragedies.

Third, a revision of the regulatory framework to introduce proactive transparency requirements for collection center operators—both public and private. Under the current system, a serious incident is reported to Health Canada, which treats it confidentially. This unilateral and opaque information chain must be redesigned to include systematic communication with the public, particularly when deaths occur.

The Positions of Patient Organizations

Among patient advocacy groups that rely on plasma-derived medications, the position is nuanced but clear. These organizations fully support increased oversight and enhanced transparency—because they know that public trust in plasma donation is the foundation of their own access to treatments. If scandals or delayed disclosures undermine this trust and reduce the number of donors, these organizations will be the first to suffer.

These associations are therefore calling for both maximum protection for donors and the maintenance of the supply—two objectives that are not contradictory but require significant regulatory and budgetary investments. They are also calling on the federal government to publicly commit to a concrete action plan in the wake of Health Canada’s revelations: what will change? By when? And what metrics will be used to track progress? These are legitimate and urgent questions.

Transparency is not the enemy of plasma donation. It is essential to its long-term survival. Without trust, there are no donations. Without donations, there are no medicines. Without medicines, patients die.

Official Responses So Far

Health Canada confirmed the four deaths in response to questions from Radio-Canada, but without holding a press conference, announcing a public action plan, or providing a timeline for the release of the investigation reports. This minimal response—acknowledging the issue without taking visible action—is characteristic of an institutional culture that prioritizes discreet crisis management over proactive transparency. It is understandable from a bureaucratic standpoint. It is unacceptable from a democratic standpoint.

Health Canada’s mandate explicitly includes protecting the health of Canadians and transparently communicating risks associated with health products. Plasma donation involves a medical risk. This risk has materialized four times in ten years in the form of deaths. Information about these deaths was not proactively disclosed to the public. Taken together, these three factors constitute, at the very least, a breach of the duty of transparency that Canadians are entitled to expect from their national health agency.

Necessary Changes

To move forward, several measures are needed. In the short term: the publication of a summary report on the four deaths, the creation of a public point of contact for the families of deceased donors, and a revision of informed consent forms to explicitly include the risk of death, however small it may be. In the medium term: the creation of the national incident registry mentioned above, the strengthening of Health Canada’s inspection teams dedicated to plasma collection centers, and the introduction of annual public reporting requirements for all operators.

In the long term, there needs to be a serious national conversation about the plasma collection model Canada wants for the coming decades. This conversation must include current and potential donors, patients who depend on plasma-derived products, the medical community, experts in medical ethics, operators—both public and private—and provincial and federal governments. It must be informed by transparent and comprehensive data. It cannot take place behind closed doors.

Four deaths in ten years: that is not a national disaster. But it is enough to demand that things change. And if we wait for the fifth death to take action, it will be a choice—not an accident.

What These Four Deaths Teach Us Collectively

Ultimately, what the revelation of these four deaths linked to plasma donation teaches us is not that plasma donation is dangerous—it is not, in the overwhelming majority of cases. Nor is it that Health Canada is incompetent—the agency manages highly complex issues with limited resources. It is not that collection centers are traps—most operate with professionalism and rigor.

What these four deaths teach us is that transparency in healthcare systems is not optional. It is a fundamental obligation to the citizens who entrust their bodies to these systems. It is the sine qua non of true informed consent. It is the foundation of a culture of continuous improvement that allows us to learn from accidents to prevent others. And it is, ultimately, the respect owed to the people who had the courage to roll up their sleeves to help others—and who deserved better than posthumous anonymity in a confidential registry.

A Call for Dignity

These four donors deserve to have their deaths serve a purpose. They deserve to have protocols reviewed in light of what happened to them. They deserve for future donors to be better informed, better protected, and better monitored. They deserve for the families they left behind to receive complete and honest answers. And they deserve for the Canadian healthcare system to have the institutional courage to take a hard look at itself, acknowledge its shortcomings, and publicly commit to doing better.

Plasma donation is an act of remarkable generosity. It saves lives every day. It deserves to be conducted with the utmost rigor, transparency, and respect for those who make it possible. That’s not too much to ask. It’s the bare minimum.

Four people died while trying to help others. The least we can do is ensure that their deaths were not in vain—and that the next donor who walks into a center walks out alive.

Signed, Jacques Pj Provost